

<b>POLICY NUMBER</b> UM_ONC_1351	<b>SUBJECT</b> Xospata™ (Gilteritinib)	<b>DEPT/PROGRAM</b> UM Dept	<b>PAGE 1 OF 2</b>
<b>DATES COMMITTEE REVIEWED</b> 01/09/19, 12/11/19, 02/12/20	<b>APPROVAL DATE</b> February 12, 2020	<b>EFFECTIVE DATE</b> March 01, 2020	<b>COMMITTEE APPROVAL DATES</b> (latest version listed last) 01/09/19, 12/11/19, 02/12/20
<b>PRIMARY BUSINESS OWNER: UM</b> <b>APPROVED BY:</b> Dr. Andrew Hertler		<b>COMMITTEE/BOARD APPROVAL</b> Utilization Management Committee	
<b>URAC STANDARDS</b> HUM 1		<b>NCQA STANDARDS</b> UM 2	<b>ADDITIONAL AREAS OF IMPACT</b>
<b>CMS REQUIREMENTS</b>	<b>STATE/FEDERAL REQUIREMENTS</b>		<b>APPLICABLE LINES OF BUSINESS</b> Commercial, Exchange, Medicaid

## I. PURPOSE

To define and describe the accepted indications for Xospata (Gilteritinib) usage in the treatment of cancer, including FDA approved indications, and off-label indications.

New Century is responsible for processing all medication requests from network ordering providers. Medications not authorized by New Century may be deemed as not approvable and therefore not reimbursable.

The use of this drug must be supported by one of the following: FDA approved product labeling, CMS-approved compendia, National Comprehensive Cancer Network (NCCN), American Society of Clinical Oncology (ASCO) clinical guidelines, or peer-reviewed literature that meets the requirements of the CMS Medicare Benefit Policy Manual Chapter 15.

## II. INDICATIONS FOR USE/INCLUSION CRITERIA

### 1. PREFERRED MEDICATION GUIDANCE FOR INITIAL REQUEST:

- When health plan Medicaid coverage provisions- including any applicable PDLs (Preferred Drug Lists)- conflict with the coverage provisions in this drug policy, health plan Medicaid coverage provisions take precedence per the **Preferred Drug Guidelines OR**
- When health plan Exchange coverage provisions- including any applicable PDLs (Preferred Drug Lists)- conflict with the coverage provisions in this drug policy, health plan Exchange coverage provisions take precedence per the **Preferred Drug Guidelines OR**
- For Health Plans that utilize NCH UM Oncology Clinical Policies as the initial clinical criteria, the **Preferred Drug Guidelines shall follow NCH L1 Pathways** when applicable, otherwise shall follow NCH drug policies: <http://pathways.newcenturyhealth.com> **AND**
- Continuation requests of previously approved non-preferred medication are not subject to this provision **AND**
- When available, generic alternatives are preferred over brand-name drugs.

### 2. Acute Myeloid Leukemia (AML)

- The member has relapsed or refractory acute myeloid leukemia (AML) with FLT-3 ITD or FLT-3 TKD mutation and Xospata (Gilteritinib) is being used as a single agent.

## III. EXCLUSION CRITERIA

- Concurrent use with other strong inhibitors or inducers of P glycoprotein (P-gp) or strong inducers of cytochrome P450 (CYP)3A.



# New Century Health

Policy #UM\_ONC\_1351  
PROPRIETARY & CONFIDENTIAL

2. The member has uncontrolled infection or Long QT Syndrome or left ventricular ejection fraction that is < 45% at screening.
3. Dosing exceeds single dose limit of Xospata (Gilteritinib) 120 mg.
4. Treatment exceeds the maximum limit of 90 (40mg) tablets/month.
5. Indications not supported by CMS recognized compendia or acceptable peer reviewed literature.

## IV. MEDICATION MANAGEMENT

Please refer to the FDA label/package insert for details regarding these topics.

## V. APPROVAL AUTHORITY

1. Review – Utilization Management Department
2. Final Approval – Utilization Management Committee

## VI. ATTACHMENTS

None

## VII. REFERENCES

1. Xospata prescribing information. Astellas Pharma US, Inc Northbrook, IL 2019.
2. Clinical Pharmacology Elsevier Gold Standard. 2020.
3. Micromedex® Healthcare Series: Thomson Micromedex, Greenwood Village, Co. 2020.
4. National Comprehensive Cancer Network. Cancer Guidelines and Drugs and Biologics Compendium. 2020.
5. AHFS Drug Information. American Society of Health-Systems Pharmacists or Wolters Kluwer Lexi-Drugs. Bethesda, MD. 2020.